WA
AVEO

WealthTrust Axiom’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

WealthTrust Axiom’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-22,347
Closed -$128K – 267
2020
Q4 		$128K Hold
22,347
– – 0.05% 218
2020
Q3 		$132K Buy
22,347
+23
+0.1% +$114 0.06% 187
2020
Q2 		$114K Buy
22,324
+17
+0.1% +$107 0.05% 186
2020
Q1 		$80K Buy
22,307
+7,998
+56% +$39.7K 0.04% 174
2019
Q4 		$89K Buy
14,309
+500
+4% +$3.68K 0.03% 212
2019
Q3 		$116K Buy
13,809
+350
+3% +$2.6K 0.04% 215
2019
Q2 		$90K Sell
13,459
-392
-3% -$3.36K 0.03% 218
2019
Q1 		$113K Buy
13,851
+11,027
+390% +$114K 0.04% 213
2018
Q4 		$45K Buy
2,824
+1,324
+88% +$29.1K 0.02% 207
2018
Q3 		$49K Buy
+1,500
New +$38.6K 0.02% 226

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

WealthTrust Axiom's AVEO Position: Q1 2021 in Review

WealthTrust Axiom sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2021, closing a stake of 22,347 shares — an estimated $128K sold.

WealthTrust Axiom first reported a position in AVEO in Q3 2018 and held it in 10 quarters. The position peaked at $132K in Q3 2020. 76 funds tracked by Wall St. Rank hold AVEO as of Q1 2021.

  • WealthTrust Axiom reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • WealthTrust Axiom sold 22,347 AVEO Pharmaceuticals, Inc. shares in Q1 2021, an estimated $128K.
  • WealthTrust Axiom first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2018 and held it in 10 quarters.
  • WealthTrust Axiom's AVEO Pharmaceuticals, Inc. position peaked at $132K in Q3 2020.
  • 76 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2021.

Based on WealthTrust Axiom's 13F filing for Q1 2021, filed 14 Apr 2021.